Minimally Invasive Thoracoscopic Heart Surgery vs. Ross Procedure: Which Is Right for You?

Introduction: The Evolution of Heart Surgery

Cardiac surgery has undergone a quiet revolution over the past two decades. Where once every open-heart operation required a full sternotomy — splitting the breastbone from top to bottom — today's patients have access to a spectrum of surgical approaches ranging from small keyhole incisions to living-tissue valve replacements that grow with the patient. Two of the most significant advances in this evolution are minimally invasive thoracoscopic cardiac surgery (微创胸腔镜心脏手术) and the Ross procedure (罗斯手术 / 肺动脉自体移植术).

These two approaches are not direct alternatives to each other — they address different problems and patient populations. But both represent the frontier of what is possible in modern cardiac surgery, and understanding them helps patients make informed decisions about their care.

Part 1: Minimally Invasive Thoracoscopic Cardiac Surgery

What Is It?

Minimally invasive thoracoscopic cardiac surgery uses small incisions (typically 2–4 cm) in the chest wall, through which a thoracoscope (a thin camera) and specialized instruments are inserted. The surgeon operates while viewing a magnified video image on a monitor, rather than looking directly into an open chest. Cardiopulmonary bypass is established through the femoral vessels in the groin rather than through the chest.

This approach can be used for a wide range of cardiac procedures that traditionally required full sternotomy:

• Mitral valve repair or replacement: The most common application; thoracoscopic mitral surgery is now the gold standard at high-volume centers
• Tricuspid valve repair: Often performed simultaneously with mitral surgery
• Atrial septal defect (ASD) closure: Repair of holes between the heart's upper chambers
• Atrial fibrillation (AF) ablation: Surgical Maze procedure or pulmonary vein isolation via thoracoscope
• Cardiac myxoma removal: Benign heart tumors
• Some aortic valve procedures: Via mini-sternotomy or right anterior thoracotomy

Robotic-Assisted Surgery

The most advanced form of minimally invasive cardiac surgery uses a robotic system (da Vinci Surgical System) in which the surgeon controls robotic arms from a console, with even greater precision and dexterity than standard thoracoscopic instruments. Robotic mitral valve repair is now performed at leading centers in Shanghai with excellent outcomes.

Advantages of Minimally Invasive Thoracoscopic Surgery

• Smaller incisions: No sternotomy; incisions are 2–4 cm; significantly better cosmesis, particularly important for younger patients and women
• Faster recovery: Hospital stay typically 4–6 days vs. 7–10 days for sternotomy; return to normal activities in 2–4 weeks vs. 6–8 weeks
• Less pain: No sternal healing; reduced post-operative pain and analgesic requirements
• Reduced blood loss: Less surgical trauma; lower transfusion rates
• Lower infection risk: No sternal wound; eliminates risk of deep sternal wound infection (a serious complication of sternotomy)
• Preserved sternal integrity: Important for patients who may need future cardiac surgery; the sternum remains intact for potential redo operations
• Equivalent outcomes: At experienced centers, minimally invasive cardiac surgery produces equivalent or superior long-term outcomes compared to conventional sternotomy for appropriate cases

Limitations and Risks

• Longer operative time: The technical complexity of working through small incisions increases operative time, particularly during the learning curve
• Femoral vessel complications: Peripheral cannulation for bypass carries a small risk of femoral artery injury, limb ischemia, or retrograde aortic dissection
• Not suitable for all patients: Severe peripheral vascular disease, prior chest surgery, obesity, or complex anatomy may preclude the minimally invasive approach
• Requires specialized expertise: Outcomes are highly dependent on surgeon and center experience; this approach should only be performed at high-volume centers
• Conversion to sternotomy: Approximately 1–3% of cases require conversion to full sternotomy due to unexpected findings or complications

Who Is a Good Candidate?

• Patients requiring mitral valve repair or replacement (ideal indication)
• Patients with ASD or cardiac tumors
• Patients who prioritize faster recovery and cosmesis
• Patients without significant peripheral vascular disease
• Patients at centers with high-volume minimally invasive cardiac surgery programs

Part 2: The Ross Procedure

What Is It?

The Ross procedure, developed by British cardiac surgeon Donald Ross in 1967, is a unique operation for aortic valve disease in which the patient's own pulmonary valve (胺动脉瓣) is used to replace the diseased aortic valve (主动脉瓣). The pulmonary valve position is then reconstructed using a donor (homograft) pulmonary valve from a tissue bank.

In essence, the Ross procedure replaces one valve problem with two valve operations — but the genius of the approach is that the patient's own pulmonary valve, now in the aortic position (called the autograft), behaves as a living tissue that:

• Grows with the patient (critical for children and young adults)
• Does not require lifelong anticoagulation (unlike mechanical valves)
• Has excellent hemodynamic performance (better than any prosthetic valve)
• Has the potential for very long durability in the aortic position

Why Is the Aortic Valve So Difficult to Replace?

The aortic valve sits at the highest-pressure point in the circulation, exposed to the full force of every heartbeat. This makes it the most demanding environment for any valve replacement:

• Mechanical valves: Extremely durable but require lifelong warfarin anticoagulation with its associated bleeding risks, dietary restrictions, and monitoring burden; also produce an audible click and have suboptimal hemodynamics
• Bioprosthetic (tissue) valves: No anticoagulation required but degenerate over time; typically last 10–15 years in older patients but fail faster in younger patients due to higher metabolic activity; redo surgery or TAVI eventually required
• TAVI (transcatheter aortic valve implantation): Catheter-based; excellent for elderly high-risk patients; long-term durability data in young patients still accumulating; valve-in-valve TAVI possible for degenerated bioprostheses

For young patients (typically under 50–60), none of these options is ideal — which is where the Ross procedure offers a compelling alternative.

Advantages of the Ross Procedure

• Living autograft: The pulmonary valve autograft is living tissue that integrates into the aortic root; it grows with the patient (essential for children), remodels, and has the potential for very long durability
• No anticoagulation: Unlike mechanical valves, the Ross procedure does not require lifelong warfarin; patients can live a normal life without anticoagulation monitoring
• Superior hemodynamics: The autograft produces the best hemodynamic performance of any aortic valve replacement option; particularly important for athletes and physically active patients
• Potential for very long durability: Long-term data from experienced centers show autograft freedom from reoperation of 85–90% at 20 years in selected patients
• Quality of life: No anticoagulation, no valve noise, excellent exercise capacity; patients often describe feeling “normal” after recovery
• Ideal for young women of childbearing age: Avoids the teratogenic and hemorrhagic risks of warfarin during pregnancy

Limitations and Risks of the Ross Procedure

• Technical complexity: The Ross procedure is one of the most technically demanding operations in cardiac surgery; outcomes are highly dependent on surgeon and center experience; should only be performed by surgeons who perform it regularly
• Double valve operation: The patient now has two valve replacements (autograft in aortic position + homograft in pulmonary position); both can potentially fail over time
• Autograft dilation: The pulmonary autograft, now exposed to systemic pressure in the aortic position, can dilate over time, causing aortic regurgitation; modern techniques (inclusion cylinder, external support) have significantly reduced this risk
• Homograft degeneration: The donor pulmonary homograft in the pulmonary position degenerates over 15–25 years; redo surgery or transcatheter pulmonary valve replacement (TPVR) is eventually required in most patients
• Not suitable for all aortic valve pathology: Bicuspid aortic valve with significant aortic root dilation, connective tissue disorders (Marfan syndrome), or active endocarditis may be relative contraindications depending on the specific anatomy
• Longer operative time and bypass time: More complex operation than standard aortic valve replacement

Who Is the Ideal Ross Procedure Candidate?

• Young patients (typically 18–50 years old) with aortic valve disease requiring surgery
• Children and adolescents with congenital aortic valve disease (the autograft grows with the child)
• Women of childbearing age who wish to avoid anticoagulation during pregnancy
• Physically active patients and athletes who require optimal hemodynamic performance
• Patients who strongly wish to avoid lifelong anticoagulation
• Patients at centers with experienced Ross procedure surgeons (>20 cases/year)

Minimally Invasive vs. Ross: A Comparison

Where to Seek Expert Cardiac Surgical Care in Shanghai

Zhongshan Hospital (中山医院), Fudan University — Cardiac Surgery

Zhongshan Hospital is one of China's premier cardiac surgical centers, with one of the highest volumes of cardiac operations in the country. Its cardiac surgery department has extensive experience in both minimally invasive thoracoscopic cardiac surgery and complex valve procedures including the Ross procedure:

• Dr. Wang Chunsheng (王春生) — Chief of Cardiac Surgery at Zhongshan Hospital, Fudan University; nationally recognized expert in valve surgery, minimally invasive cardiac surgery, and complex cardiac reconstruction; one of China's most experienced cardiac surgeons

Renji Hospital (仁济医院), Shanghai Jiao Tong University — Cardiology

For pre-operative cardiac evaluation, echocardiography, and interventional cardiology assessment prior to surgical planning:

• Cardiology at Renji Hospital Shanghai — Comprehensive cardiac evaluation and interventional cardiology services

Questions to Ask Your Cardiac Surgeon

• Am I a candidate for minimally invasive thoracoscopic surgery, or does my anatomy or pathology require sternotomy?
• For aortic valve disease: am I a candidate for the Ross procedure, and what are the alternatives given my age and lifestyle?
• How many minimally invasive / Ross procedures does your center perform per year, and what are your outcomes data?
• What is the expected durability of my valve replacement, and what will redo surgery or transcatheter options look like in 15–20 years?
• Will I need anticoagulation, and for how long?
• What are the specific risks of the recommended approach for my anatomy?

How CMCS Can Help

Choosing between cardiac surgical approaches requires expert evaluation, detailed imaging, and a surgeon with specific experience in the recommended technique. CMCS connects international patients with Shanghai's leading cardiac surgeons, providing:

• Priority appointments with cardiac surgeons and cardiologists at Zhongshan Hospital and other leading centers
• Pre-consultation review of echocardiography, CT angiography, and cardiac catheterization reports
• Medical interpretation during all surgical consultations and family discussions
• Coordination of pre-operative cardiac evaluation and anesthesia assessment
• Post-operative follow-up coordination including cardiac rehabilitation and valve monitoring

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com